RPRX
Royalty Pharma Plc
58.30$
+1.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 10.9% | 7.8% | 9.7% | 14.6% | 9.9% | 9.9% | 10.5% | 8.3% | 9.6% | 3.2% | 7.2% | 4.1% | |
| 5.9% | 2.9% | 5.2% | 10.0% | 5.3% | 5.1% | 6.2% | 3.4% | 4.9% | 3.2% | 3.0% | 4.1% | |
| 10.6% | 7.5% | 9.5% | 14.5% | 9.8% | 9.7% | 10.3% | 8.1% | 4.9% | 3.2% | 3.1% | 4.2% | |
| 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 4.6% | 4.5% | 4.1% | 4.5% | |
| – | – | – | – | -4.4% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 0.0% | – | 5.0% | 4.8% | 4.7% | 4.7% | 4.7% | |
| 0.1% | 0.0% | – | 0.0% | 83.0% | – | – | 82.6% | 0.0% | – | 83.5% | – | |
| 39.5% | 38.4% | 38.9% | 44.8% | 43.1% | 43.2% | 44.4% | 48.1% | 50.3% | 50.5% | 49.9% | 50.6% | |
| 0.8% | 1.0% | 0.8% | 1.6% | 6.5% | 6.9% | 6.7% | 6.6% | 2.7% | 3.2% | 2.7% | 3.2% | |
| – | – | – | – | 5.5% | 5.5% | 5.7% | 5.5% | 2.0% | 1.9% | 1.9% | 1.9% | |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.1% | 0.2% | 0.1% | 0.1% | 0.2% | |
| 38.7% | 37.5% | 38.1% | 43.1% | 36.6% | 36.3% | 37.6% | 38.2% | 44.3% | 43.7% | 43.3% | 43.3% | |
| 38.7% | 39.8% | 40.3% | 36.7% | 38.1% | 38.1% | 38.0% | 34.6% | 33.2% | 33.0% | 34.8% | 34.5% | |
| 13.5% | 15.4% | 15.0% | 13.5% | 15.3% | 15.6% | 14.1% | 12.1% | 11.9% | 12.0% | 12.7% | 12.4% | |
| 3.8% | 3.7% | 3.7% | 3.4% | 3.3% | 3.2% | 3.3% | 3.1% | 2.9% | 2.9% | 2.8% | 2.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.